查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1978846

消化性潰瘍治療市場：2026-2032年全球市場預測（依給藥途徑、品牌類型、劑型、藥物類別、銷售管道、最終用戶和分銷管道分類）

Peptic Ulcer Drugs Market by Route Of Administration, Brand Type, Dosage Form, Drug Class, Sales Channel, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，胃潰瘍治療市場價值將達到 49.9 億美元，到 2026 年將成長至 52.6 億美元，到 2032 年將達到 77 億美元，複合年成長率為 6.39%。

主要市場統計數據
基準年 2025 49.9億美元
預計年份：2026年 52.6億美元
預測年份 2032 77億美元
複合年成長率 (%) 6.39%

簡要概述當前影響消化性潰瘍治療格局和相關人員決策的臨床、商業性和供應方面趨勢。

消化性潰瘍的治療仍然是胃腸病學實踐的基石，其臨床重點在於控制症狀、促進黏膜癒合和預防併發症。抑酸藥物的進步和臨床通訊協定的改進改變了臨床醫生診斷和治療消化性潰瘍的方式，使許多治療決策從住院治療轉移到門診和居家照護護理。患者和醫療保健提供者現在受益於對幽門螺旋桿菌的作用、長期持續抑酸治療的影響以及在慢性治療中平衡療效和安全性的更深入了解。

科學進步、監管審查和分銷創新如何推動消化性潰瘍治療在整個護理路徑中的策略重組。

在科學進步、監管重新評估和患者就醫途徑不斷發展的推動下，消化性潰瘍治療的治療和商業性格局正在經歷變革性變化。科學方面，對胃酸功能和黏膜保護機制的深入理解，明確了何時以及如何應用強效抑酸療法，從而促成​​了指南的修訂和處方實踐的改進。同時，真實世界安全性數據和藥物安全監測的發現，加強了對長期治療的審查，引入了更為謹慎的停藥框架，優先考慮適當的治療持續時間和監測，以及促進患者和醫生之間協作決策的工具。

本研究評估了近期關稅變化如何促使消化性潰瘍藥物的生產和分銷進行供應鏈重組、近岸外包和全面商業策略。

近期影響醫藥原料和成品的關稅措施和貿易政策調整，對整個產業的供應鏈經濟和籌資策略帶來了壓力。某些進口藥用活性成分和輔料關稅的提高，迫使生產商重新評估其採購體系，許多公司正在權衡不斷上漲的接收成本與供應商突然變更帶來的營運風險之間的利弊。進口關稅也可能影響下游決策，例如契約製造合作夥伴的選擇、庫存佈局以及在多個司法管轄區維持分散式生產的可行性。

從給藥途徑、銷售管道通路、品牌類型、劑型、最終用戶、分銷管道和藥物類別等觀點進行詳細的觀點，從而實現策略選擇。

細分市場層面的區分揭示了臨床應用、商業策略和營運要求的顯著差異，這些差異影響著產品的開發、行銷和交付方式。給藥途徑將情況分為口服療法和腸外療法。口服療法適用於常規治療和非處方藥（OTC），而腸外療法則用於急性住院治療或無法耐受口服給藥的患者。銷售管道對市場准入提出了不同的要求。作為非處方藥，其重點在於面向消費者的訊息、包裝和零售分銷；而處方藥則需要與處方醫生進行溝通、協商藥物推廣方案以及開展藥物安全監測項目。

美洲、歐洲、中東和非洲以及亞太地區的監管、報銷和供應鏈現實情況，是市場進入和商業化方法的差異化因素。

區域趨勢對法律規範、報銷標準和供應鏈結構產生深遠影響，進而對策略規劃產生重大影響。在美洲，監管機構和支付者強調循證藥物清單、成本控制機制以及公私合作採購模式，這些模式旨在評估藥物已證實的臨床價值和成本效益。這種環境鼓勵製藥公司投資於穩健的臨床項目、真實世界數據（REW）生成以及與支付方的合作策略，以在治療獲益和預算限制之間取得平衡。

決定製藥公司、非專利生產商、契約製造生產商、經銷商和服務合作夥伴競爭地位的策略行動和能力。

在消化性潰瘍治療領域運作的產業相關人員必須平衡創新、品質和規模，才能保持競爭力。大型跨國製藥公司往往投資於廣泛的臨床開發項目、完善的藥物安全監測系統以及支持品牌藥和學名藥的全球製造地。這些公司優先考慮監管多元化、策略聯盟以及應對複雜競標環境的能力，尤其是在醫院採購和國家處方集發揮關鍵作用的領域。

加強供應韌性、監管應對力和全通路銷售系統的實用策略，以在胃潰瘍治療領域保持競爭優勢。

在瞬息萬變的消化性潰瘍治療市場中，產業領導企業應優先考慮供應鏈韌性、監管靈活性和差異化的病人參與，以掌握機會並降低風險。加強供應商多元化策略，投資區域生產和雙重採購安排，可以保障關鍵劑型的供應連續性，同時降低貿易中斷和關稅波動帶來的風險。此外，企業還應透過實施供應商監控的高級分析、增強批次級可追溯性以及主動進行污染風險評估，實現品管系統的現代化，從而維護產品完整性並確保符合監管要求。

嚴謹的混合方法研究框架，結合對專家的初步訪談、對法規和臨床方面的二次分析以及供應鏈映射，為檢驗的研究結果提供了支持。

本分析採用多方面研究方法，結合一手訪談、二手文獻綜述以及結構化的供應鏈和監管檢驗，以確保獲得平衡且經得起驗證的見解。我們諮詢了臨床實踐、藥品生產、分銷和採購領域的專家，以收集關於治療管理、品質和生產挑戰以及商業性需求的多元觀點。此外，我們還使用了包括同儕審查的臨床文獻、監管建議、行業指導文件和公開文件在內的二級資訊來源，以提供權威的、基於證據的臨床和政策觀察。

作為胃潰瘍治療領域持續表現的支柱，我們強調韌性、證據產生以及基於以客戶為中心的執行的結論整合。

消化性潰瘍治療領域的特徵是臨床需求持續存在、監管不斷加強以及商業性模式不斷演變，所有這些因素都要求行業相關人員採取適應性策略。在臨床方面，有效抑制胃酸分泌和控制感染疾病仍然是重中之重，而安全性考量和患者偏好正在改變長期用藥的實踐方式。在營運方面，供應鏈的穩健性和合規性是影響市場持續性和品牌聲譽的關鍵因素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：消化性潰瘍治療市場：依給藥途徑分類

  • 口服
  • 腸外

第9章：按品牌類型分類的消化性潰瘍治療藥物市場

  • 品牌商品
  • 非專利的

第10章 按劑型分類的消化性潰瘍治療藥物市場分佈

  • 膠囊
  • 注射藥物
  • 藥片

第11章 消化性潰瘍治療市場：依藥物類別分類

  • H2受體拮抗劑
    • 西咪替丁
    • 法莫替丁
    • 尼扎替丁
    • 雷尼替丁
  • 質子幫浦阻斷劑
    • Esomeprazole
    • 蘭索拉唑
    • 奧美拉唑
    • 泮托拉唑
    • Rabeprazole

第12章：消化性潰瘍治療市場：依銷售管道分類

  • 非處方藥
  • 處方藥

第13章：消化性潰瘍治療市場：依最終用戶分類

  • 居家醫療
  • 醫院
  • 門診部

第14章 消化性潰瘍治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第15章：消化性潰瘍治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：消化性潰瘍治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 消化性潰瘍治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國消化性潰瘍治療市場

第19章：中國消化性潰瘍治療市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cadila Healthcare Ltd.
  • Century Pharmaceuticals Ltd.
  • Daewoong Pharmaceutical Co. LTD.
  • Dr. Reddy's Laboratories Ltd
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Medopharm Pvt Ltd
  • Merck KGaA
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Pharmanova India Drugs Pvt. Ltd.
  • Redhill Biopharma Ltd
  • Rosemont Pharmaceuticals Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-2A0283E25692

The Peptic Ulcer Drugs Market was valued at USD 4.99 billion in 2025 and is projected to grow to USD 5.26 billion in 2026, with a CAGR of 6.39%, reaching USD 7.70 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.99 billion
Estimated Year [2026] USD 5.26 billion
Forecast Year [2032] USD 7.70 billion
CAGR (%) 6.39%

A concise orientation to current clinical, commercial, and supply-side dynamics shaping the peptic ulcer therapeutics environment and stakeholder decisions

Peptic ulcer therapeutics remain a cornerstone of gastroenterology practice, with a clinical focus that spans symptom control, mucosal healing, and complication prevention. Advances in acid suppression pharmacology and refined clinical pathways have reshaped how clinicians diagnose and manage peptic ulcer disease, shifting many care decisions from inpatient settings to ambulatory and home care environments. Patients and providers now benefit from a deeper understanding of Helicobacter pylori's role, the long-term implications of sustained acid suppression, and the need to balance efficacy with safety in chronic therapy.

Clinically, proton pump inhibitors have become the dominant modality for achieving profound and durable acid suppression, while H2 receptor antagonists continue to play a supporting role in selected scenarios and as short-term therapies. The therapeutic landscape has been influenced by regulatory actions, product recalls, and evolving OTC access models, which together affect prescriber behavior and patient self-management. Concurrently, the supply chain that brings these medicines from API production through finished-dose manufacturing to distribution and point-of-care has become more complex, influenced by global sourcing, regulatory harmonization, and evolving reimbursement practices.

This executive summary synthesizes current dynamics affecting the peptic ulcer drugs arena, emphasizing the interplay between clinical evidence, regulatory developments, commercialization channels, and operational realities. The aim is to provide decision-makers with a clear, actionable perspective that integrates therapeutic performance considerations with commercial and supply-side realities, supporting informed strategy development across product portfolios, distribution networks, and stakeholder engagement plans.

How scientific advances, regulatory scrutiny, and distribution innovation are driving a strategic reconfiguration of peptic ulcer therapeutics across care pathways

The therapeutic and commercial landscape for peptic ulcer drugs is undergoing transformative shifts driven by scientific advances, regulatory recalibration, and changes in patient access pathways. On the scientific front, improved mechanistic understanding of gastric acid physiology and mucosal protection has refined when and how aggressive acid suppression is deployed, prompting guideline revisions and more nuanced prescribing practices. At the same time, real-world safety data and pharmacovigilance findings have increased scrutiny of long-term therapy, leading to more deliberate deprescribing frameworks and shared decision-making tools that prioritize appropriate duration and monitoring.

Regulatory and quality challenges have also catalyzed change. Manufactured product integrity, API sourcing practices, and contamination incidents have led to tighter oversight and an emphasis on supplier transparency. These pressures are accelerating industry adoption of enhanced quality assurance measures and dual-sourcing strategies to protect continuity of supply. Commercially, the lines between prescription and over-the-counter access have blurred, expanding patient choice while forcing manufacturers and distributors to adapt marketing, packaging, and patient education efforts to a more retail-oriented context.

Lastly, digital and distribution innovations are redefining patient touchpoints. Telemedicine follow-ups, remote pharmacy services, and the growth of online pharmacy platforms have shifted where and how patients obtain therapies, creating opportunities to embed adherence support and clinical decision aids into the care continuum. Together, these shifts are compelling incumbent players to revisit product positioning, invest in quality and regulatory compliance, and design omnichannel strategies that reflect new patient journeys and payer priorities.

Assessing how recent tariff shifts are prompting supply chain redesign, nearshoring, and integrated commercial strategies across peptic ulcer drug production and distribution

Recent tariff actions and trade policy adjustments affecting pharmaceutical inputs and finished products are exerting pressure on supply chain economics and sourcing strategies across the industry. Increased duties on certain imported active pharmaceutical ingredients and excipients have prompted manufacturers to reassess their procurement footprints, with many evaluating the trade-offs between higher landed costs and the operational risks of rapid supplier substitution. Import tariffs can also influence downstream decisions about contract manufacturing partner selection, inventory positioning, and the viability of maintaining decentralized production across multiple jurisdictions.

From an operational viewpoint, tariffs have accelerated the adoption of nearshoring and regional manufacturing strategies aimed at mitigating exposure to cross-border duties and transport volatility. These shifts often require capital investment in manufacturing capacity and quality systems, and they can extend lead times for new product introductions. For companies that rely heavily on complex global supply chains, tariffs have encouraged the development of more robust scenario planning and stress-testing of supplier ecosystems, as well as stronger contractual protections around pricing and supply continuity.

On the commercial side, tariff-driven cost pressures are influencing pricing strategies, negotiations with payers, and channel incentives. Payers and procurement teams are increasingly attentive to total cost of ownership, which includes logistics, tariff burden, and regulatory compliance overhead. In response, manufacturers and distributors are exploring value-based contracting, bundled procurement arrangements, and collaborative sourcing partnerships to preserve access while managing margin compression. These adaptive measures underscore the need for integrated commercial and supply chain planning to ensure that tariff impacts are anticipated, managed, and, where possible, converted into competitive advantage.

Deep segmentation perspectives that connect administration routes, sales channels, brand types, dosage forms, end users, distribution channels, and drug classes to strategic choices

Segment-level distinctions reveal meaningful differences in clinical use, commercial strategy, and operational requirements that shape how products are developed, marketed, and delivered. Route of administration divides the landscape between oral therapies, which dominate routine management and OTC access, and parenteral options that are reserved for acute hospital care or patients unable to tolerate oral dosing. Sales channels create divergent go-to-market imperatives: over-the-counter availability prioritizes consumer-facing messaging, packaging, and retail distribution, while prescription drugs require prescriber engagement, formulary access negotiations, and pharmacovigilance programs.

Brand type introduces another axis of strategic differentiation. Branded products often compete on differentiation, clinical evidence, and service offerings such as patient support programs, whereas generics compete primarily on cost competitiveness, manufacturing scale, and distribution efficiency. Dosage form matters operationally and commercially; capsules, injections, and tablets each entail distinct manufacturing processes, stability considerations, and patient acceptance dynamics that influence product lifecycle planning. End-user segmentation further informs deployment choices, with home care favoring convenience, simplified regimens, and patient education tools, hospitals requiring injectable and IV-compatible formulations alongside robust supply logistics, and outpatient clinics balancing cost, adherence, and ease of administration.

Distribution channel nuances are equally consequential. Hospital pharmacies maintain tight integration with inpatient workflows and clinical governance, online pharmacies prioritize digital engagement, compliance, and last-mile logistics, and retail pharmacies emphasize shelf placement, promotional activity, and point-of-sale counseling. Finally, drug class characteristics underpin both clinical and commercial strategy. H2 receptor antagonists and proton pump inhibitors differ in onset, potency, and duration of effect, with subclasses and individual molecules such as cimetidine, famotidine, nizatidine, ranitidine, esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole exhibiting distinct pharmacokinetic and safety profiles that inform prescribing guidance, labeling strategies, and competitor positioning. Understanding these layered segmentation dynamics is essential for aligning R&D priorities, manufacturing investments, and market access efforts with the realities of patient care and payer expectations.

Regional regulatory, reimbursement, and supply chain realities across the Americas, EMEA, and Asia-Pacific that shape differentiated market entry and commercialization approaches

Regional dynamics shape regulatory frameworks, reimbursement norms, and supply chain architectures in ways that materially affect strategic planning. In the Americas, regulatory authorities and payer systems emphasize evidence-based formularies, cost containment mechanisms, and a mix of public and private procurement approaches that reward demonstrated clinical value and cost-effectiveness. This environment incentivizes manufacturers to invest in robust clinical programs, real-world evidence generation, and payer engagement strategies that reconcile therapeutic benefits with budgetary constraints.

In Europe, the Middle East, and Africa, heterogeneity in regulatory capacity and reimbursement policies requires nuanced market entry strategies. European markets often feature centralized or harmonized approval pathways coupled with stringent HTA processes, while markets in the Middle East and Africa present a mosaic of procurement models, varying levels of clinical infrastructure, and differing demands for local regulatory documentation. Manufacturers and distributors must therefore tailor their licensing, pricing, and supply chain approaches to reflect local regulatory expectations and procurement behaviors.

The Asia-Pacific region presents a blend of rapid innovation adoption in some high-income markets and large-volume, cost-sensitive demand in emerging economies. Policymakers in the region have increasingly prioritized local manufacturing capacity and pharmaceutical self-sufficiency, which affects foreign manufacturers' market access strategies and partnership models. Across all regions, digital distribution and telehealth adoption are changing patient access patterns, necessitating region-specific digital engagement and e-commerce strategies to capture new customer journeys and preserve adherence outcomes.

Strategic behaviors and capabilities of manufacturers, generics producers, contract manufacturers, distributors, and service partners that determine competitive positioning

Industry players operating in the peptic ulcer therapeutics space must balance innovation, quality, and scale to remain competitive. Large multinational pharmaceutical firms tend to invest in broad clinical development programs, extensive pharmacovigilance infrastructure, and global manufacturing footprints that support both branded and generic portfolios. These firms prioritize regulatory diversification, strategic alliances, and the ability to navigate complex tendering environments, especially where hospital procurement and national formularies play a pivotal role.

Generic manufacturers and specialty producers focus on manufacturing excellence and cost leadership, leveraging high-volume production and process optimization to compete on price and availability. Contract manufacturing organizations and API suppliers are central to maintaining continuity of supply, particularly as firms pursue multi-sourcing strategies to mitigate quality and geopolitical risks. Distributors and pharmacy chains, including online platforms, play a critical role in shaping patient access and adherence through integrated logistics, patient education initiatives, and digital engagement tools.

Across this ecosystem, service providers that deliver regulatory support, quality assurance auditing, and cold chain logistics add strategic value by reducing time-to-market and lowering the operational burden on manufacturers. Partnerships between commercial organizations and clinical stakeholders-such as hospitals and specialty clinics-are increasingly common, as these collaborations facilitate formulary access, real-world evidence collection, and post-launch surveillance activities that reinforce product positioning and reimbursement negotiations.

Actionable strategies for strengthening supply resilience, regulatory readiness, and omnichannel commercialization to sustain competitive advantage in peptic ulcer therapeutics

Industry leaders should prioritize supply chain resilience, regulatory agility, and differentiated patient engagement to capture opportunities and mitigate risks in the evolving peptic ulcer therapeutics landscape. Strengthening supplier diversification strategies and investing in regional manufacturing or dual-sourcing arrangements will reduce vulnerability to trade disruptions and tariff volatility while supporting continuity of supply for critical dosage forms. Concurrently, companies should modernize quality oversight by implementing advanced analytics for supplier monitoring, enhanced lot-level traceability, and proactive contamination risk assessment to preserve product integrity and regulatory compliance.

On commercialization, organizations must design tailored omnichannel strategies that reflect the distinct dynamics of over-the-counter and prescription markets. This includes digital outreach and adherence support for home care patients, targeted clinical engagement for hospital and outpatient clinic prescribers, and optimized retail and online distribution models that address convenience and compliance. Value demonstration efforts should focus on real-world effectiveness, safety profiles, and total cost of care implications to align with payer priorities and to support favorable formulary positioning.

Finally, leaders should embed regulatory intelligence and scenario planning into strategic decision-making. Anticipatory regulatory mapping, early dialogue with authorities, and investment in post-market surveillance infrastructure will accelerate responsive labeling and supply adjustments when safety signals or policy shifts occur. By integrating operational resilience, commercial precision, and regulatory foresight, companies can not only withstand market disruptions but also create defensible competitive advantages.

A rigorous mixed-method research framework combining primary expert engagement, secondary regulatory and clinical analysis, and supply chain mapping to underpin validated insights

This analysis was developed using a multi-method research approach that combined primary interviews, secondary literature review, and structured supply chain and regulatory analysis to ensure balanced and validated insights. Subject-matter experts from clinical practice, pharmaceutical manufacturing, distribution, and procurement were consulted to capture diverse perspectives on therapeutic management, quality and manufacturing challenges, and commercial imperatives. Secondary sources included peer-reviewed clinical literature, regulatory advisories, industry guidance documents, and public filings to ground clinical and policy observations in authoritative evidence.

Supply chain assessments relied on supplier mapping, review of public customs and trade data, and analysis of logistics pathways to identify common vulnerabilities and mitigation strategies. Regulatory analysis drew on public agency communications, safety alerts, and guidance documents to track evolving compliance expectations and reporting obligations. Throughout the research process, findings were triangulated across independent sources to validate conclusions and to expose areas of uncertainty.

Limitations of the methodology include reliance on publicly available regulatory communications and expert interviews that may not capture proprietary commercial arrangements or the most recent confidential supplier negotiations. To mitigate these constraints, the study emphasizes transparent assumptions, cites regulatory positions where applicable, and recommends follow-up primary research for organizations seeking deep-dive, proprietary intelligence or custom scenario modeling.

Concluding synthesis emphasizing resilience, evidence generation, and customer-centric execution as pillars for sustained performance in peptic ulcer therapeutics

The peptic ulcer therapeutics arena is characterized by enduring clinical needs, ongoing regulatory vigilance, and evolving commercial modalities that together demand adaptive strategies from industry participants. Clinically, effective acid suppression and the integration of infection management remain priority imperatives, while safety considerations and patient preference are reshaping long-term use. Operationally, supply chain robustness and regulatory compliance are central determinants of market continuity and brand reputation.

Commercial success will increasingly depend on the ability to align product portfolios with differentiated patient journeys, to demonstrate real-world value to payers, and to deploy flexible manufacturing and sourcing models that withstand geopolitical and trade-related shocks. Organizations that proactively invest in quality assurance, omnichannel patient engagement, and regulatory intelligence will be best positioned to translate clinical efficacy into sustainable market access and commercial performance. These conclusions point toward a strategic roadmap built on resilience, evidence, and customer-centric execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peptic Ulcer Drugs Market, by Route Of Administration

  • 8.1. Oral
  • 8.2. Parenteral

9. Peptic Ulcer Drugs Market, by Brand Type

  • 9.1. Branded
  • 9.2. Generic

10. Peptic Ulcer Drugs Market, by Dosage Form

  • 10.1. Capsule
  • 10.2. Injection
  • 10.3. Tablet

11. Peptic Ulcer Drugs Market, by Drug Class

  • 11.1. H2 Receptor Antagonists
    • 11.1.1. Cimetidine
    • 11.1.2. Famotidine
    • 11.1.3. Nizatidine
    • 11.1.4. Ranitidine
  • 11.2. Proton Pump Inhibitors
    • 11.2.1. Esomeprazole
    • 11.2.2. Lansoprazole
    • 11.2.3. Omeprazole
    • 11.2.4. Pantoprazole
    • 11.2.5. Rabeprazole

12. Peptic Ulcer Drugs Market, by Sales Channel

  • 12.1. Over The Counter
  • 12.2. Prescription Drugs

13. Peptic Ulcer Drugs Market, by End User

  • 13.1. Home Care
  • 13.2. Hospitals
  • 13.3. Outpatient Clinics

14. Peptic Ulcer Drugs Market, by Distribution Channel

  • 14.1. Hospital Pharmacies
  • 14.2. Online Pharmacies
  • 14.3. Retail Pharmacies

15. Peptic Ulcer Drugs Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Peptic Ulcer Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Peptic Ulcer Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Peptic Ulcer Drugs Market

19. China Peptic Ulcer Drugs Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Abbott Laboratories
  • 20.6. AbbVie Inc.
  • 20.7. AstraZeneca PLC
  • 20.8. Boehringer Ingelheim International GmbH
  • 20.9. Cadila Healthcare Ltd.
  • 20.10. Century Pharmaceuticals Ltd.
  • 20.11. Daewoong Pharmaceutical Co. LTD.
  • 20.12. Dr. Reddy's Laboratories Ltd
  • 20.13. Eisai Co. Ltd.
  • 20.14. F. Hoffmann-La Roche Ltd.
  • 20.15. GlaxoSmithKline PLC
  • 20.16. Hikma Pharmaceuticals PLC
  • 20.17. Medopharm Pvt Ltd
  • 20.18. Merck KGaA
  • 20.19. Mylan N.V.
  • 20.20. Novartis AG
  • 20.21. Pfizer Inc.
  • 20.22. Pharmanova India Drugs Pvt. Ltd.
  • 20.23. Redhill Biopharma Ltd
  • 20.24. Rosemont Pharmaceuticals Limited
  • 20.25. Takeda Pharmaceutical Company Limited
  • 20.26. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEPTIC ULCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PEPTIC ULCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA PEPTIC ULCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY CIMETIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY FAMOTIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY NIZATIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RANITIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ESOMEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY LANSOPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OMEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PANTOPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RABEPRAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 185. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 188. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 215. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 217. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. G7 PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 225. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 228. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. NATO PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL PEPTIC ULCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA PEPTIC ULCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA PEPTIC ULCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)